Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-08-02 Sale |
2024-08-05 4:25 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
688 | $20.14 | $13,857 | 219,179 (Direct) |
View |
| 2024-06-04 Sale |
2024-06-06 5:43 pm |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
964 | $23.89 | $23,033 | 176,079 (Direct) |
View |
| 2024-06-04 Sale |
2024-06-06 5:42 pm |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
964 | $23.89 | $23,027 | 14,210 (Direct) |
View |
| 2024-06-04 Sale |
2024-06-06 5:42 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
964 | $23.89 | $23,025 | 89,421 (Direct) |
View |
| 2024-03-01 Sale |
2024-03-05 4:09 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
3,324 | $16.02 | $53,253 | 251,235 (Direct) |
View |
| 2024-03-01 Sale |
2024-03-05 4:08 pm |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
2,519 | $16.02 | $40,358 | 160,098 (Direct) |
View |
| 2024-02-28 Sale |
2024-02-29 4:38 pm |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
2,078 | $16.14 | $33,545 | 318,965 (Direct) |
View |
| 2024-02-28 Sale |
2024-02-29 4:28 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
2,303 | $16.14 | $37,177 | 326,479 (Direct) |
View |
| 2023-11-07 Sale |
2023-11-08 4:22 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
382 | $12.65 | $4,832 | 124,511 (Direct) |
View |
| 2023-09-01 Sale |
2023-09-05 4:24 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
883 | $21.82 | $19,265 | 99,650 (Direct) |
View |
| 2023-09-01 Sale |
2023-09-05 4:24 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
294 | $21.82 | $6,414 | 209,825 (Direct) |
View |
| 2023-09-01 Sale |
2023-09-05 4:23 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
273 | $21.82 | $5,956 | 124,893 (Direct) |
View |
| 2023-08-02 Sale |
2023-08-04 4:02 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,144 | $30.25 | $34,607 | 100,533 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-06-05 Exercise |
2024-06-07 4:06 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
124,373 | $22.82 | 470,608 (Indirect) |
View |
| 2024-06-05 Option Award |
2024-06-06 6:37 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Ocean Allyson J Director |
10,282 | $0 | 10,282 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 6:13 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Madden Martin J. Director |
10,282 | $0 | 25,902 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:55 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Hung David Director |
10,282 | $0 | 19,423 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:43 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Stafford Kristin Director |
10,282 | $0 | 10,282 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:43 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
10,282 | $0 | 176,079 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:42 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
10,282 | $0 | 14,210 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:42 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
10,282 | $0 | 89,421 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-06 5:09 pm |
N/A 2034-06-04 |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
10,282 | $0 | 12,819 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:43 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
258,597 | $16.3 | 376,215 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:38 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
258,597 | $16.3 | 318,965 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:36 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
181,017 | $16.3 | 218,610 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:35 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
206,877 | $16.3 | 296,226 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:33 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Leupin Nicolas Chief Medical Officer |
129,298 | $16.3 | 129,298 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:33 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Giladi Moshe Chief Science Officer |
129,298 | $16.3 | 147,945 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:30 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
206,877 | $16.3 | 242,200 (Direct) |
View |
| 2023-12-31 Option Award |
2024-02-29 4:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
128 | $12.69 | 242,200 (Direct) |
View |
| 2024-02-27 Option Award |
2024-02-29 4:28 pm |
2025-02-27 2034-02-26 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
118,954 | $16.3 | 326,479 (Direct) |
View |
| 2023-12-31 Option Award |
2024-02-29 4:28 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
3 | $12.69 | 326,479 (Direct) |
View |
Ownership |
2024-01-12 4:57 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X EVP, Pres., Novocure Oncology |
0 | $0 | 227,173 (Direct) |
View |
Ownership |
2023-12-20 4:23 pm |
N/A N/A |
NovoCure Ltd | NVCR | Giladi Moshe Chief Science Officer |
0 | $0 | 61,032 (Direct) |
View |
| 2023-10-31 Option Award |
2023-11-03 4:08 pm |
N/A N/A |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
37,593 | $0 | 95,197 (Direct) |
View |
| 2023-10-31 Option Award |
2023-11-03 4:08 pm |
2024-10-31 2033-10-30 |
NovoCure Ltd | NVCR | Puri Michal Nath Chief Human Resources Officer |
57,604 | $13.3 | 95,197 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
7,752 | $7.15 | 117,793 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
2,480 | $11.44 | 117,793 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
7,736 | $11.46 | 117,793 (Direct) |
View |
| 2023-10-31 Exercise |
2023-11-02 4:20 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
17,968 | $0 | 117,793 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
305 | $35.28 | 89,349 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
366 | $35.28 | 210,119 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
367 | $35.28 | 125,166 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
357 | $35.28 | 66,447 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
288 | $35.28 | 35,195 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
367 | $35.28 | 101,677 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-06 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
367 | $35.28 | 13,989 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:05 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
10,130 | $0 | 172,074 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:05 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
10,130 | $0 | 10,205 (Direct) |
View |